ArticleFrontiers in neurology2025
Platelet count and sleep quality in immune thrombocytopenia: correlation with 5-hydroxytryptamine and therapeutic implications of platelet-5-HT-melatonin axis dysregulation.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune thrombocytopenia (ITP) disrupts platelet homeostasis via autoimmune mechanisms, yet its systemic effects beyond bleeding risk remain poorly characterized. Sleep disturbances are frequently reported in ITP patients, but the relationship between thrombocytopenia, serotonergic signaling, and sleep architecture remains undefined. This study investigates whether platelet dynamics modulate sleep quality through the "platelet-5-HT-melatonin axis" and explores therapeutic implications of this axis in ITP. Methods: In a prospective longitudinal cohort of 87 ITP patients (baseline platelet count: 28.7 ± 15.2 × 10 Results: At baseline, ITP patients had significantly higher PSQI scores than controls (12.4 ± 3.8 vs. 6.2 ± 2.1, Conclusion: ITP-associated thrombocytopenia disrupts sleep architecture through serotonergic dysregulation and chronic inflammation. Standard glucocorticoid therapy not only restores platelet counts but also ameliorates sleep quality and fatigue, highlighting the therapeutic potential of platelet-targeted interventions for comorbid sleep disorders. These findings advocate for routine sleep assessment in ITP management and integration of 5-HT-modulating strategies into comprehensive care frameworks to address the hematologic-immunologic-sleep axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.